OBJECTIVE: The objective of this study was to compare the rate of severe cardiovascular events and death in children who use attention-deficit/hyperactivity disorder (ADHD) medications versus nonusers. PATIENTS AND METHODS: We performed a large cohort study using data from 2 administrative databases. All children aged 3 to 17 years with a prescription for an amphetamine, atomoxetine, or methylphenidate were included and matched with up to 4 nonusers on the basis of data source, gender, state, and age. Cardiovascular events were validated using medical records. Proportional hazards regression was used to calculated hazard ratios. RESULTS: We identified 241 417 incident users (primary cohort). No statistically significant difference between incident users and nonusers was observed in the rate of validated sudden death or ventricular arrhythmia (hazard ratio: 1.60 [95% confidence interval (CI): 0.19-13.60]) or all-cause death (hazard ratio: 0.76 [95% CI: 0.52-1.12]). None of the strokes identified during exposed time to ADHD medications were validated. No myocardial infarctions were identified in ADHD medication users. No statistically significant difference between prevalent users and nonusers (secondary cohort) was observed (hazard ratios for validated sudden death or ventricular arrhythmia: 1.43 [95% CI: 0.31-6.61]; stroke: 0.89 [95% CI: 0.11-7.11]; stroke/myocardial infarction: 0.72 [95% CI: 0.09-5.57]; and all-cause death: 0.77 [95% CI: 0.56-1.07). CONCLUSIONS: The rate of cardiovascular events in exposed children was very low and in general no higher than that in unexposed control subjects. Because of the low number of events, we have limited ability to rule out relative increases in rate.
OBJECTIVE: The objective of this study was to compare the rate of severe cardiovascular events and death in children who use attention-deficit/hyperactivity disorder (ADHD) medications versus nonusers. PATIENTS AND METHODS: We performed a large cohort study using data from 2 administrative databases. All children aged 3 to 17 years with a prescription for an amphetamine, atomoxetine, or methylphenidate were included and matched with up to 4 nonusers on the basis of data source, gender, state, and age. Cardiovascular events were validated using medical records. Proportional hazards regression was used to calculated hazard ratios. RESULTS: We identified 241 417 incident users (primary cohort). No statistically significant difference between incident users and nonusers was observed in the rate of validated sudden death or ventricular arrhythmia (hazard ratio: 1.60 [95% confidence interval (CI): 0.19-13.60]) or all-cause death (hazard ratio: 0.76 [95% CI: 0.52-1.12]). None of the strokes identified during exposed time to ADHD medications were validated. No myocardial infarctions were identified in ADHD medication users. No statistically significant difference between prevalent users and nonusers (secondary cohort) was observed (hazard ratios for validated sudden death or ventricular arrhythmia: 1.43 [95% CI: 0.31-6.61]; stroke: 0.89 [95% CI: 0.11-7.11]; stroke/myocardial infarction: 0.72 [95% CI: 0.09-5.57]; and all-cause death: 0.77 [95% CI: 0.56-1.07). CONCLUSIONS: The rate of cardiovascular events in exposed children was very low and in general no higher than that in unexposed control subjects. Because of the low number of events, we have limited ability to rule out relative increases in rate.
Authors: Susan R Heckbert; Charles Kooperberg; Monika M Safford; Bruce M Psaty; Judith Hsia; Anne McTiernan; J Michael Gaziano; William H Frishman; J David Curb Journal: Am J Epidemiol Date: 2004-12-15 Impact factor: 4.897
Authors: Sean Hennessy; Hedi Schelleman; Gregory W Daniel; Warren B Bilker; Stephen E Kimmel; James Guevara; Mark J Cziraky; Brian L Strom Journal: Pharmacoepidemiol Drug Saf Date: 2010-09 Impact factor: 2.890
Authors: W D Rosamond; A R Folsom; L E Chambless; C H Wang; P G McGovern; G Howard; L S Copper; E Shahar Journal: Stroke Date: 1999-04 Impact factor: 7.914
Authors: Christopher J Kratochvil; Timothy E Wilens; Laurence L Greenhill; Haitao Gao; Kurt D Baker; Peter D Feldman; Douglas L Gelowitz Journal: J Am Acad Child Adolesc Psychiatry Date: 2006-08 Impact factor: 8.829
Authors: Sean Hennessy; Charles E Leonard; Cristin P Freeman; Rajat Deo; Craig Newcomb; Stephen E Kimmel; Brian L Strom; Warren B Bilker Journal: Pharmacoepidemiol Drug Saf Date: 2010-06 Impact factor: 2.890
Authors: Madelyn S Gould; B Timothy Walsh; Jimmie Lou Munfakh; Marjorie Kleinman; Naihua Duan; Mark Olfson; Laurence Greenhill; Thomas Cooper Journal: Am J Psychiatry Date: 2009-06-15 Impact factor: 18.112
Authors: Laurel A Habel; William O Cooper; Colin M Sox; K Arnold Chan; Bruce H Fireman; Patrick G Arbogast; T Craig Cheetham; Virginia P Quinn; Sascha Dublin; Denise M Boudreau; Susan E Andrade; Pamala A Pawloski; Marsha A Raebel; David H Smith; Ninah Achacoso; Connie Uratsu; Alan S Go; Steve Sidney; Mai N Nguyen-Huynh; Wayne A Ray; Joe V Selby Journal: JAMA Date: 2011-12-12 Impact factor: 56.272
Authors: David Goldberg; Ivo C Ditah; Kia Saeian; Mona Lalehzari; Andrew Aronsohn; Emmanuel C Gorospe; Michael Charlton Journal: Gastroenterology Date: 2017-01-11 Impact factor: 22.682
Authors: Esther W Chan; Kirin Q L Liu; Celine S L Chui; Chor-Wing Sing; Lisa Y L Wong; Ian C K Wong Journal: Br J Clin Pharmacol Date: 2015-06-01 Impact factor: 4.335
Authors: Mark Olfson; Cecilia Huang; Tobias Gerhard; Almut G Winterstein; Stephen Crystal; Paul D Allison; Steven C Marcus Journal: J Am Acad Child Adolesc Psychiatry Date: 2011-12-20 Impact factor: 8.829